2.Unilateral Pulmonary Edema: A Rare Initial Presentation of Cardiogenic Shock due to Acute Myocardial Infarction.
Jeong Hun SHIN ; Seok Hwan KIM ; Jinkyu PARK ; Young Hyo LIM ; Hwan Cheol PARK ; Sung Il CHOI ; Jinho SHIN ; Kyung Soo KIM ; Soon Gil KIM ; Mun K HONG ; Jae Ung LEE
Journal of Korean Medical Science 2012;27(2):211-214
Cardiogenic unilateral pulmonary edema (UPE) is a rare clinical entity that is often misdiagnosed at first. Most cases of cardiogenic UPE occur in the right upper lobe and are caused by severe mitral regurgitation (MR). We present an unusual case of right-sided UPE in a patient with cardiogenic shock due to acute myocardial infarction (AMI) without severe MR. The patient was successfully treated by percutaneous coronary intervention and medical therapy for heart failure. Follow-up chest Radiography showed complete resolution of the UPE. This case reminds us that AMI can present as UPE even in patients without severe MR or any preexisting pulmonary disease affecting the vasculature or parenchyma of the lung.
Acute Disease
;
Aged
;
Coronary Angiography
;
Diagnosis, Differential
;
Heart Atria/ultrasonography
;
Heart Failure/diagnosis/etiology
;
Humans
;
Male
;
Mitral Valve Insufficiency/ultrasonography
;
Myocardial Infarction/complications/*diagnosis/therapy
;
Pulmonary Edema/*diagnosis/etiology/therapy
;
Shock, Cardiogenic/*diagnosis/etiology/therapy
;
Tomography, X-Ray Computed
3.Stevens-Johnson Syndrome and Hypothermia Associated with Anti-tuberculosis Medication in a Patient with Heart Failure.
Sang-Ok JUNG ; Min-Ji CHO ; Dong-Il PARK ; Sun-Young KIM ; Ju-Ock KIM ; Sung-Soo JUNG ; Hee-Sun PARK ; Jeong-Eun LEE ; Jae-Young MOON ; Chae-Uk CHUNG
Chinese Medical Journal 2015;128(20):2837-2838
4.Peripartum Cardiomyopathy: Review of the Literature.
Pradipta BHAKTA ; Binay K BISWAS ; Basudeb BANERJEE
Yonsei Medical Journal 2007;48(5):731-747
Peripartum cardiomyopathy (PPCM) is a rare but serious form of cardiac failure affecting women in the last months of pregnancy or early puerperium. Clinical presentation of PPCM is similar to that of systolic heart failure from any cause, and it can sometimes be complicated by a high incidence of thromboembolism. Prior to the availability of echocardiography, diagnosis was based only on clinical findings. Recently, inclusion of echocardiography has made diagnosis of PPCM easier and more accurate. Its etiopathogenesis is still poorly understood, but recent evidence supports inflammation, viral infection and autoimmunity as the leading causative hypotheses. Prompt recognition with institution of intensive treatment by a multidisciplinary team is a prerequisite for improved outcome. Conventional treatment consists of diuretics, beta blockers, vasodilators, and sometimes digoxin and anticoagulants, usually in combination. In resistant cases, newer therapeutic modalities such as immunomodulation, immunoglobulin and immunosuppression may be considered. Cardiac transplantation may be necessary in patients not responding to conventional and newer therapeutic strategies. The role of the anesthesiologist is important in perioperative and intensive care management. Prognosis is highly related to reversal of ventricular dysfunction. Compared to historically higher mortality rates, recent reports describe better outcome, probably because of advances in medical care. Based on current information, future pregnancy is usually not recommended in patients who fail to recover heart function. This article aims to provide a comprehensive updated review of PPCM covering etiopathogeneses, clinical presentation and diagnosis, as well as pharmacological, perioperative and intensive care management and prognosis, while stressing areas that require further research.
Anesthesia, Obstetrical/adverse effects
;
Echocardiography, Doppler
;
Female
;
Heart Failure/*diagnosis/etiology/therapy
;
Humans
;
Incidence
;
Mortality
;
Pregnancy
;
Pregnancy Complications, Cardiovascular/*diagnosis/etiology/therapy
;
Prognosis
;
Recurrence
;
Risk Factors
;
Ventricular Dysfunction, Left/ultrasonography
5.Pleural and pericardial empyema in a patient with continuous ambulatory peritoneal dialysis peritonitis.
Jong Hoon LEE ; Young Sun NOH ; Youn Hee LEE ; In Ae JANG ; Ho Chul SONG ; Euy Jin CHOI ; Yong Kyun KIM
The Korean Journal of Internal Medicine 2013;28(5):626-627
No abstract available.
Anti-Bacterial Agents/therapeutic use
;
Cardiac Tamponade/etiology
;
Drainage
;
Empyema, Pleural/diagnosis/*etiology/microbiology/therapy
;
Heart Diseases/diagnosis/*etiology/microbiology/therapy
;
Humans
;
Kidney Failure, Chronic/*therapy
;
Male
;
Methicillin-Resistant Staphylococcus aureus/isolation & purification
;
Middle Aged
;
Pericardial Effusion/etiology
;
Pericardial Window Techniques
;
Pericardiocentesis
;
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects
;
Peritonitis/diagnosis/drug therapy/*etiology/microbiology
;
Pleural Effusion/etiology
;
Staphylococcal Infections/diagnosis/drug therapy/*etiology/microbiology
;
Tomography, X-Ray Computed
;
Treatment Outcome
6.Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
Dong Geum SHIN ; Iksung CHO ; Briain O HARTAIGH ; Hee Sun MUN ; Hye Young LEE ; Eui Seock HWANG ; Jin Kyu PARK ; Jae Sun UHM ; Hui Nam PAK ; Moon Hyoung LEE ; Boyoung JOUNG
Yonsei Medical Journal 2015;56(6):1552-1558
PURPOSE: Electric cardioversion has been successfully used in terminating symptomatic atrial fibrillation (AF). Nevertheless, largescale study about the acute cardiovascular events following electrical cardioversion of AF is lacking. This study was performed to evaluate the incidence, risk factors, and clinical consequences of acute cardiovascular events following electrical cardioversion of AF. MATERIALS AND METHODS: The study enrolled 1100 AF patients (mean age 60+/-11 years) who received cardioversion at four tertiary hospitals. Hospitalizations for stroke/transient ischemic attack, major bleedings, and arrhythmic events during 30 days post electric cardioversion were assessed. RESULTS: The mean duration of anticoagulation before cardioversion was 95.8+/-51.6 days. The mean International Normalized Ratio at the time of cardioversion was 2.4+/-0.9. The antiarrhythmic drugs at the time of cardioversion were class I (45%), amiodarone (40%), beta-blocker (53%), calcium-channel blocker (21%), and other medication (11%). The success rate of terminating AF via cardioversion was 87% (n=947). Following cardioversion, 5 strokes and 5 major bleedings occurred. The history of stroke/transient ischemic attack (OR 6.23, 95% CI 1.69-22.90) and heart failure (OR 6.40, 95% CI 1.77-23.14) were among predictors of thromboembolic or bleeding events. Eight patients were hospitalized for bradyarrhythmia. These patients were more likely to have had a lower heart rate prior to the procedure (p=0.045). Consequently, 3 of these patients were implanted with a permanent pacemaker. CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion.
Aged
;
Amiodarone/therapeutic use
;
Anti-Arrhythmia Agents/therapeutic use
;
Atrial Fibrillation/*complications/epidemiology/*therapy
;
Bradycardia/epidemiology/etiology
;
Cardiovascular Diseases/epidemiology/*etiology
;
Electric Countershock/*methods
;
Female
;
Heart Failure/epidemiology/etiology
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Risk Factors
;
Stroke/diagnosis/epidemiology/*etiology
;
Treatment Outcome
7.Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Seung Ah LEE ; Hong Mi CHOI ; Hye Jin PARK ; Su Kyoung KO ; Hae Young LEE
The Korean Journal of Internal Medicine 2014;29(3):315-324
BACKGROUND/AIMS: This meta-analysis compared the effects of amlodipine besylate, a charged dihydropyridine-type calcium channel blocker (CCB), with other non-CCB antihypertensive therapies regarding the cardiovascular outcome. METHODS: Data from seven long-term outcome trials comparing the cardiovascular outcomes of an amlodipine-based regimen with other active regimens were pooled and analyzed. RESULTS: The risk of myocardial infarction was significantly decreased with an amlodipine-based regimen compared with a non-CCB-based regimen (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.84 to 0.99; p = 0.03). The risk of stroke was also significantly decreased (OR, 0.84; 95% CI, 0.79 to 0.90; p < 0.00001). The risk of heart failure increased slightly with marginal significance for an amlodipine-based regimen compared with a non-CCB-based regimen (OR, 1.14; 95% CI, 0.98 to 1.31; p = 0.08). However, when compared overall with beta-blockers and diuretics, amlodipine showed a comparable risk. Amlodipine-based regimens demonstrated a 10% risk reduction in overall cardiovascular events (OR, 0.90; 95% CI, 0.82 to 0.99; p = 0.02) and total mortality (OR, 0.95; 95% CI, 0.91 to 0.99; p = 0.01). CONCLUSIONS: Amlodipine reduced the risk of total cardiovascular events as well as all-cause mortality compared with non-CCB-based regimens, indicating its benefit for high-risk cardiac patients.
Amlodipine/*therapeutic use
;
Antihypertensive Agents/*therapeutic use
;
Blood Pressure/*drug effects
;
Calcium Channel Blockers/*therapeutic use
;
Chi-Square Distribution
;
Clinical Trials as Topic
;
Heart Failure/etiology/mortality/*prevention & control
;
Humans
;
Hypertension/complications/diagnosis/*drug therapy/mortality/physiopathology
;
Myocardial Infarction/etiology/mortality/*prevention & control
;
Odds Ratio
;
Risk Factors
;
Stroke/etiology/mortality/*prevention & control
;
Treatment Outcome